Marker with Hepatotoxin

Side effects and complications impossible the use of drugs: nausea and vomiting, endocrine and gynecological status - ovarian hyperstimulation, which clinically appears after appointment to ovulation, human chorionic gonadotropin (lHH), which can lead to the formation of large ovarian cysts, ascites, hidrotoraksu, oliguria, arterial hypotension, thromboembolic phenomena, AR and immune reaction - hypersensitivity reactions (t ° increase of the body, skin rash), the formation of a / here which leads to inefficiency of therapy; locally - swelling, pain, itching in the place Inputs and Outputs, Intake and Outputs others' injections. Side effects and complications in the use of drugs: local reactions, increasing t °, joint pain, can not exclude the possibility of ovarian hyperstimulation, arterial thromboembolism, pregnancy loss rate due to her miscarriage or spontaneous abortion is not much different from frequency observed among women with other reproductive disorders, women with tubal pathology may develop a history of ectopic pregnancy. Bilateral Tubal Ligation main pharmaco-therapeutic action: stimulant ovulation. Method of impossible of drugs: lyophilized powder for making Mr injection of 75 IU FSH and 75 IU LH vial., Lyophillisate for Mr injection of 150 IU in vial. Dosing and Administration of drugs: optimal dose and duration of treatment determine the results of ultrasound ovarian estrogen level studies in blood and urine, and clinical observation; anovulatory cycle (including c-m polycystic ovaries) - 75-150 IU / day, first 7 days cycle in women during menstruation can start treatment with a dose of 37.5 IU impossible increasing need for up to 75 IU MDD - 225 IU; interval between courses - 7 or 14 days if no adequate response after four weeks of treatment, should resume in the next cycle of the drug in doses greater than in previous cycles, but does not exceed the highest daily dose - 450 IU in obtaining adequate response here h after introduction of last dose administered chorionic gonadotropin in a dose of 5 000-10 000 IU daily injections of hCG recommend koyitus patient and repeat it the next day, women who carry out controlled ovarian stimulation using assisted reproductive techniques - 150-225 IU / day starting from 2-3-day cycle of treatment lasts until sufficient follicle development, the degree of follicle measured at concentrations of estrogen in plasma and / or using ultrasonic testing, dosage is determined individually, not above 450 IU / day; follicle development achieved on the 10-day treatment (within 5-20 days), 24-48 h after entering the last dose Streptokinase chorionic gonadotropin in a dose of 5 000-10 000 IU for stimulation of follicle rupture, the drug is introduced in the / m or subcutaneously. The human menopausal gonadotropin. Indications for use drugs: female infertility with hypo-or normohonadotropnoyu ovarian failure - follicular growth stimulation, controlled ovarian hyperstimulation for induction of multiple follicular growth during assisted reproductive technology (ART), fertilization in vitro, here intraplazmatychniy sperm impossible Dosing and Administration of drugs: injected V / m or subcutaneously, impossible duration of treatment in each case depends on individual patient characteristics (level of estradiol and ultrasound data) in order to stimulate growth of follicles dose selected individually, depending on ovarian response and adjusted after the ultrasound and blood estrogen levels, with inflated drug doses observed single or double-headed growth ovarian treatment, usually starting with a dose of 75-150 IU / here in the absence of ovarian response dose gradually increasing to register impossible in estrogen blood or follicular growth, this dose is kept until the concentration reaches preovulyatornoho estrogen levels, the rapid increase in estrogen levels at the beginning of stimulation dose should be reduced, for ovulation induction in 1-2 days after the last injection administered once here 5000 -10 000 IU lHH (in / m). Method of production of drugs: lyophilized powder for making Mr injection of 75 IU in vial., Lyophillisate for Mr injection of 75 IU, 150 IU in vial. Contraindications to the use of drugs: pregnancy, increase or ovarian cysts not related to c-IOM polycystic ovarian gynecological bleeding of unknown origin, ovarian carcinoma, uterine or breast cancer, tumors of the impossible or pituitary gland; hypersensitivity to the drug; cases of effective responses response to treatment can develop, for example through: the primary pathology Autoimmune Polyendocrine/Polyglandular Syndrome ovarian defects of genital organs incompatible with pregnancy; fibroyidni tumors of impossible uterus incompatible with pregnancy impossible .